Darzalex Faspro® (with Janssen)

About Halozyme Therapeutics

Halozyme Therapeutics has established itself as a dominant force in subcutaneous drug delivery through its validated ENHANZE® technology platform. The company's strategy successfully combines high-margin royalty and milestone revenue from over a dozen partnerships with leading pharma companies (including Roche, Takeda, and Pfizer) with direct sales from its commercial products, HYLENEX® and XYOSTED®. This dual business model provides diversified revenue streams and leverages a single, scalable platform technology to reduce treatment burden and improve patient outcomes across multiple therapeutic areas. Halozyme's commercial validation and expanding partnership pipeline position it for sustained growth as the industry shifts towards convenient, patient-centric administration.

Therapeutic Areas

Other Multiple Myeloma Drugs